Global Biologics Manufacturing Market 2018-2022| Introduction of New Biologic Drugs to Spur Growth| Technavio
LONDON--(BUSINESS WIRE)--Aug 31, 2018--The global biologics manufacturing market 2018-2022 is expected to post a CAGR of more than 9% during the forecast period, according to the latest market research report by .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180831005463/en/
Technavio has published a new market research report on the global biologics manufacturing market from 2018-2022. (Graphic: Business Wire)
A key factor driving the growth of the market is the introduction of new biologic drugs for treating diseases. The demand for biologics for the more effective treatment of diseases is growing as synthetic drugs have several limitations. Therefore, the development of new biologics for the treatment of existing disorders and rare conditions is expected to fuel the growth of the biologics manufacturing industry during the forecast period.
This market research report on the also provides an analysis of the most important trends expected to impact the market outlook during the forecast period. Technavio classifies an emerging trend as a major factor that has the potential to significantly impact the market and contribute to its growth or decline.
In this report, Technavio highlights the rise in partnership between biopharma companies and biotechnology startups as one of the key emerging trends in the global biologics development process market:
Global biologics manufacturing market: Rise in partnership between biopharma companies and biotechnology startups
The significant growth of the biologics industry and biotech companies in the past few years has encouraged several major traditional biopharma companies to collaborate with the biotechnology startups to develop novel biologic drugs. Traditional biopharma companies are collaborating, investing, licensing the technology, as well as acquiring startup companies to leverage their expertise for faster drug development.
“Several medical companies are working on advanced drug development for medical care that can possibly change the market landscape of the biologics industry in the coming years. Plenty of biotech companies are in the early to late stage of clinical testing and are expected to bring low-cost drugs to the market during the forecast period, which can considerably impact the business process of large pharma companies. Hence, traditional biopharma companies are investing in building partnerships with such startups during the early phase of drug development,” says a senior analyst at Technavio for research on infectious and rare diseases.
Global biologics manufacturing market: Segmentation analysis
This market research report segments the global biologics manufacturing process market by product (biologics and biosimilars), by technology (in-house and outsourced) and geographical regions (APAC, EMEA, and the Americas).
The Americas led the market in 2017 with a market share of more than 52%, followed by APAC and EMEA respectively. Although APAC held the smallest share of the market, it is expected to witness the maximum increase in its market share over the forecast period.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Market LandscapeMarket ecosystem Market characteristics Market segmentation analysis
Market SizingMarket definition Market size and forecast
Five Forces Analysis
Geographical SegmentationRegional comparison Key leading countries
Vendor LandscapeVendors covered Vendor classification Market positioning of vendors Competitive scenario
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180831005463/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL RESEARCH SCIENCE GENERAL HEALTH
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 08/31/2018 03:41 PM/DISC: 08/31/2018 03:41 PM